A topical fluorescent analogue for virtual hematoxylin and eosin histology in point-of-care ex vivo microscopy

2015 ◽  
Author(s):  
Katherine Elfer ◽  
Andrew Sholl ◽  
Christopher Miller ◽  
J. Quincy Brown
2002 ◽  
Vol 48 (11) ◽  
pp. 2030-2043 ◽  
Author(s):  
Glenn F Billman ◽  
Amy B Hughes ◽  
Golde G Dudell ◽  
Elizabeth Waldman ◽  
Lisa M Adcock ◽  
...  

Abstract Background: The management of critically ill infants and neonates includes frequent determination of arterial blood gas, electrolyte, and hematocrit values. An objective of attached point-of-care patient monitoring is to provide clinically relevant data without the adverse consequences associated with serial phlebotomy. Methods: We prospectively determined the mean difference (and SD of the difference) from laboratory methods of an in-line, ex vivo monitor, the VIA LVM Blood Gas and Chemistry Monitoring System® (VIA LVM Monitor; Metracor Technologies, Inc.), in 100 critically ill neonates and infants at seven children’s hospitals. In doing so, we examined monitor stability with continuous use. In vivo patient test results from laboratory benchtop analyzers were compared with those from the VIA LVM Monitor on paired samples. In a separate in vitro comparison, benchtop analyzer and monitor test results were compared on whole-blood split samples. Results: A total of 1414 concurrent, paired-sample measurements were obtained. The mean differences (SD of differences) from laboratory methods and r values for the combined data for the VIA LVM Monitor from the seven sites were 0.001 (0.026) and 0.97 for pH, 0.7 (3.6) mmHg and 0.94 for Pco2, 4.2 (9.6) mmHg and 0.98 for Po2, 0.0 (2.9) mmol/L and 0.87 for sodium, 0.1 (0.2) mmol/L and 0.96 for potassium, and 0.3% (2.9%) and 0.90 for hematocrit. Performance results were similar among the study sites with increasing time of monitor use and between in vivo paired-sample and in vitro split-sample test results. Conclusion: The VIA LVM Monitor can be used to assess critically ill neonates and infants.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3207-3207
Author(s):  
Graham Smith ◽  
Loida Sheridan-Smith ◽  
Margaret A. Smith ◽  
Sam Pambakian ◽  
Jim Campbell

Abstract Platelet function is a vital factor in preventing bleeding irrespective of circulating platelet number. As a result, patients often have their surgery cancelled due to taking Aspirin or related medications. Similarly, patients bleed in the ITU setting when their counts and humoral coagulation are normal. This raises the concept of exhausted platelets which is often difficult to prove. The availability of a bedside technique which enumerates patients’ "functional" platelets, which is reliable and reproducible, represents a major step forward in determining whether these patients require platelet transfusion. Helena Laboratories, Beaumont, Texas, US have produced blood collection bottles which are coated with platelet agonists equine collagen (C), risocetin (R) or arachidonic acid (AA) in addition to 3.2mg sodium citrate. Our group is the first in Europe to use these bottles in association with point of care testing instrumentation (Horiba ABX Pentra, Chicksands, Beds, England). Samples were taken from normal, renal dialysis, cardiac catheterisation, haematological and ITU patients into K2EDTA and the above bottles and treated identically prior to counting. Samples taken into K2EDTA served as baseline controls whilst free platelets in the synchronously taken agonist samples represented non functional platelets (the normal functional ones having aggregated onto the inside wall of the tube). Data on 54 normal subjects showed that, when using C, only 6.2+/−3.1% of platelets were non functional (NF). Similar figures were found for R and AA. In dialysis patients with eGFR 4–25mls/min (n=32), the R NF% was 58.07+/−17.59%. In a similar group of renal patients on dialysis and Aspirin (n=12), the R NF% was 60.55+/−21.86% which was not statistically different from the non Aspirin group (p=0.955). In cardiac patients, all of whom were on Aspirin, C NF% was 35.23+/−23.12%, AA NF% 51.94+/−23.5% and R NF% 51.53+/−19.04%. C vs AA showed a significant p-value of 0.003and C vs R p=0.002. AA vs R was not significant at p=0.94. These data show that ristocetin is a surprisingly sensitive method of detecting non functional platelets in renal and Aspirin users. Classically, ristocetin is not thought of being a detector of Aspirin effect although data from Sloand et al. JASN (1997) 8(5),799 shows that ristocetin may detect renal effect on platelet GpIb-IX (CD42b). These data demonstrate the potential value of ristocetin aggregation ex vivo in determining the need for platelet transfusion and may provide clinicians with an improved and more logical rationale for such an expensive therapy.


2021 ◽  
Author(s):  
Qiu Meiyu ◽  
Li Pei

Clustered regularly interspaced short palindromic repeats (CRISPR) technology, an easy, rapid, cost-effective, and precise gene-editing technique, has revolutionized diagnostics and gene therapy. Fast and accurate diagnosis of diseases is essential for point-of-care-testing (POCT) and specialized medical institutes. The CRISPR-associated (Cas) proteins system shed light on the new diagnostics methods at point-of-care (POC) owning to its advantages. In addition, CRISPR/Cas-based gene-editing technology has led to various breakthroughs in gene therapy. It has been employed in clinical trials for a variety of untreatable diseases, including cancer, blood disorders, and other syndromes. Currently, the clinical application of CRISPR/Cas has been mainly focused on ex vivo therapies. Recently, tremendous efforts have been made in the development of ex vivo gene therapy based on CRISPR-Cas9. Despite these efforts, in vivo CRISPR/Cas gene therapy is only in its initial stage. Here, we review the milestones of CRISPR/Cas technologies that advanced the field of diagnostics and gene therapy. We also highlight the recent advances of diagnostics and gene therapy based on CRISPR/Cas technology. In the last section, we discuss the strength and significant challenges of the CRISPR/Cas technology for its future clinical usage in diagnosis and gene therapy.


2020 ◽  
Vol 185 (Supplement_1) ◽  
pp. 110-120
Author(s):  
Sayf A Said ◽  
Carlos X Ordeñana ◽  
Majid Rezaei ◽  
Brian A Figueroa ◽  
Srinivasan Dasarathy ◽  
...  

Abstract Introduction Ex-vivo normothermic limb perfusion (EVNLP) has been proven to preserve limb viability better than standard cold storage. Perfusates containing packed red blood cells (pRBC) improve outcomes when compared to acellular perfusates. Limitations of pRBC-based perfusion include limited availability, need for cross match, mechanical hemolysis, and activation of pro-inflammatory proteins. Hemoglobin-based oxygen carrier (HBOC)-201 (Hemopure) is a solution of polymerized bovine hemoglobin, characterized by low immunogenicity, no risk of hemolytic reaction, and enhanced convective and diffusive oxygen delivery. This is a preliminary study on the feasibility of EVNLP using HBOC-201 as an oxygen carrier. Materials and Methods Three porcine forelimb perfusions were performed using an established EVNLP model and an HBOC-201-based perfusate. The perfusion circuit included a roller pump, oxygenator, heat exchanger, and reservoir. Electrolytes, limb temperature, weight, compartment pressure, nerve conduction, and perfusion indicated by indocyanine green angiography and infra-red thermography were monitored. Histological evaluation was performed with hematoxylin and eosin and electron microscopy. Results Three limbs were perfused for 21.3 ± 2.1 hours. Muscle contractility was preserved for 10.6 ± 2.4 hours. Better preservation of the mitochondrial ultrastructure was evident at 12 hours in contrast to crystallization and destruction features in the cold-storage controls. Conclusions An HBOC-201-EVNLP produced outcomes similar to RBC-EVNLP with preservation of muscle contractility and mitochondrial structure.


2018 ◽  
Vol 37 (4) ◽  
pp. S55-S56
Author(s):  
A.S. Andreasson ◽  
W. Laroy ◽  
J.H. Dark ◽  
A.J. Fisher

2016 ◽  
Vol 65 (05) ◽  
pp. 356-361 ◽  
Author(s):  
Katharina Waubke ◽  
Anika Pehl ◽  
Thorsten Steinfeldt ◽  
Detlef Bartsch ◽  
Andreas Kirschbaum

Background Every anatomical lung resection requires the airtight closure of at least one bronchus. In current clinical practice, these bronchi are sealed with sutures or staplers. This study investigated in an ex vivo pig model whether a new bipolar sealing device MARSEAL (KLS Martin, Tuttlingen, Germany) could be an alternative for this purpose. Methods Complete bronchial trees were prepared free from pig heart–lung blocks that were removed at a slaughterhouse. These preparations were taken to the laboratory, and main, lobar, and segmental bronchi were closed using sutures, staples, or bipolar sealing. Each trachea was then intubated and connected to a ventilating device. The initial airtight closure of the bronchus was first tested with lung-protective ventilation. After 15 minutes of ventilation, the inspiratory ventilation pressure was slowly increased and the burst pressure (in mbar) was recorded. Each group included 12 bronchus closures. Group mean burst pressures were compared using a nonparametric test (Mann–Whitney U test). The significance level was p < 0.05. Results The main bronchi closed both stapler magazines or sutures were all initially airtight during ventilation. The mean burst pressure was 60 ± 0 mbar for staplers and 57.92 ± 5.8 mbar for sutures. In contrast, 50% of main bronchi sealed with MARSEAL devices (5 or 10 mm) leaked air from the beginning. This was also noted in all lobar bronchi sealed with the MARSEAL 5-mm device and 80% of those sealed with the MARSEAL 10-mm device. The mean burst pressure of initially airtight lobar bronchi was 12.7 ± 7.25 mbar. In contrast, all segmental bronchi (mean width: 1.6 cm) were airtight when ventilated. Mean burst pressure was 14.64 ± 9.1 mbar with the MARSEAL 5-mm device and 29.64 ± 21.3 mbar with the MARSEAL 10-mm device. Histological investigation of the preparations (with hematoxylin and eosin staining) showed intact cartilaginous structures that were largely unaffected by bipolar coagulation. The airtight sealing of the segmental bronchi resulted from fusion of the peribronchial tissue and not the cartilage. Conclusion Bipolar sealing is an inappropriate tool for the closure of the bronchi in comparison to suture or stapling.


Sign in / Sign up

Export Citation Format

Share Document